Understanding and treating heart problems caused by cancer drugs
Official title: Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity
Funded at Beckman Research Institute/city of Hope · NIH-11049672 · Data updated 2026-11-12
This study is looking at how a lung cancer medication called osimertinib might affect heart health, especially in causing heart problems, and aims to find ways to protect your heart while you’re being treated for cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | May 15, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $697,952 |
| NIH project number | 1R01HL173308-01A1 |
| Project ID | NIH-11049672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients undergoing treatment with tyrosine kinase inhibitors, particularly those experiencing heart-related side effects.
✕Less likely to help
Patients who are not receiving tyrosine kinase inhibitors or do not have heart issues related to cancer treatment may not benefit from this research.
What this research studies
This research investigates how tyrosine kinase inhibitors (TKIs), particularly osimertinib used in lung cancer treatment, can lead to heart issues such as left ventricular dysfunction. The study aims to uncover the molecular mechanisms behind this cardiotoxicity and identify potential therapeutic targets to prevent or mitigate these heart problems. Using advanced techniques like single nucleus-RNA sequencing and human stem cell-derived heart cells, researchers will explore the effects of osimertinib on heart function. Patients may benefit from new strategies to protect their hearts while receiving cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect patients' hearts from damage caused by cancer treatments.
How similar studies have gone: Previous research has shown promising results in understanding and mitigating cardiotoxicity from cancer therapies, suggesting that this approach could lead to significant advancements.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Rhee, June-Wha — Beckman Research Institute/city of Hope
- Study coordinator: Rhee, June-Wha
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.